Literature DB >> 1680791

The effects of twice and four times daily zidovudine on p24 antigenaemia in CDC stage II/III patients.

S Gill1, A Tang, M Cordery, B Spacey, G Kelly, N T Bateman, D Barlow.   

Abstract

Reduction of HIV p24 antigenaemia by zidovudine was investigated in 34 HIV antibody-positive, asymptomatic patients in a randomised, double-blind, placebo-controlled trial. Zidovudine was shown to lower p24 antigen levels as effectively when administered twice daily as when administered four times daily. Serum levels of p24 antigen varied little over 18 weeks in patients taking placebo.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1680791      PMCID： PMC1194606          DOI： 10.1136/sti.67.1.15

Source DB:  PubMed          Journal:  Genitourin Med        ISSN： 0266-4348


  9 in total

1.  Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS.

Authors:  J M Lange; D A Paul; H G Huisman; F de Wolf; H van den Berg; R A Coutinho; S A Danner; J van der Noordaa; J Goudsmit
Journal:  Br Med J (Clin Res Ed)       Date:  1986-12-06

Review 2.  Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides.

Authors:  R Yarchoan; H Mitsuya; C E Myers; S Broder
Journal:  N Engl J Med       Date:  1989-09-14       Impact factor: 91.245

3.  Effect of zidovudine on serum human immunodeficiency virus core antigen levels. Results from a placebo-controlled trial.

Authors:  R E Chaisson; M D Leuther; J P Allain; S Nusinoff-Lehrman; G S Boone; D Feigal; P Volberding
Journal:  Arch Intern Med       Date:  1988-10

4.  Anemia and erythropoiesis in patients with the acquired immunodeficiency syndrome (AIDS) and Kaposi sarcoma treated with zidovudine.

Authors:  R E Walker; R I Parker; J A Kovacs; H Masur; H C Lane; S Carleton; L E Kirk; H R Gralnick; A S Fauci
Journal:  Ann Intern Med       Date:  1988-03       Impact factor: 25.391

5.  Effect of zidovudine on serum human immunodeficiency virus antigen levels in symptom-free subjects.

Authors:  F de Wolf; J M Lange; J Goudsmit; P Cload; J de Gans; P T Schellekens; R A Coutinho; A P Fiddian; J van der Noordaa
Journal:  Lancet       Date:  1988-02-20       Impact factor: 79.321

6.  The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.

Authors:  M A Fischl; D D Richman; N Hansen; A C Collier; J T Carey; M F Para; W D Hardy; R Dolin; W G Powderly; J D Allan
Journal:  Ann Intern Med       Date:  1990-05-15       Impact factor: 25.391

7.  Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial.

Authors:  K Gelmon; J S Montaner; M Fanning; J R Smith; J Falutz; C Tsoukas; J Gill; G Wells; M O'Shaughnessy; M Wainberg
Journal:  AIDS       Date:  1989-09       Impact factor: 4.177

8.  Human immunodeficiency virus (HIV) antigenemia (p24) in the acquired immunodeficiency syndrome (AIDS) and the effect of treatment with zidovudine (AZT).

Authors:  G G Jackson; D A Paul; L A Falk; M Rubenis; J C Despotes; D Mack; M Knigge; E E Emeson
Journal:  Ann Intern Med       Date:  1988-02       Impact factor: 25.391

9.  Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.

Authors:  P A Volberding; S W Lagakos; M A Koch; C Pettinelli; M W Myers; D K Booth; H H Balfour; R C Reichman; J A Bartlett; M S Hirsch
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245
  9 in total
  2 in total

Review 1.  Zidovudine: a review of pharmacoeconomic and quality-of-life considerations for its use in patients with human immunodeficiency virus.

Authors:  H D Langtry; K J Palmer; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-04       Impact factor: 4.981

2.  Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy.

Authors:  Rachel Jordan; Lisa Gold; Carole Cummins; Chris Hyde
Journal:  BMJ       Date:  2002-03-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.